Exogenous low‐dose IL‐2 can modulate immunity by increasing the number of circulating Treg cells, ameliorating GVHD without exacerbating the GVL effect, as shown in several animal experiments [175, 187, 188]. This evidence concerns the gene IL2 and graft versus host disease.